US 12,128,215 B2
Drug delivery device with integrated optical-based glucose monitor
Steven Cardinali, Tewksbury, MA (US); David Nazzaro, Groveland, MA (US); and Ian McLaughlin, Groton, MA (US)
Assigned to INSULET CORPORATION, Acton, MA (US)
Filed by Insulet Corporation, Acton, MA (US)
Filed on Sep. 28, 2021, as Appl. No. 17/487,570.
Claims priority of provisional application 63/085,853, filed on Sep. 30, 2020.
Prior Publication US 2022/0096749 A1, Mar. 31, 2022
Int. Cl. A61M 5/172 (2006.01)
CPC A61M 5/1723 (2013.01) [A61M 2205/0238 (2013.01); A61M 2205/3313 (2013.01); A61M 2230/201 (2013.01)] 20 Claims
OG exemplary drawing
 
6. A wearable drug delivery device, comprising:
a needle deployment component including a cannula and first optical conduit deployable into a user, the cannula operable to deliver a liquid drug to the user;
a glucose monitor including an optical sensor, the optical sensor operable to measure a light output received via the optical conduit, wherein the first optical conduit comprises a first optical fiber, wherein a first end of the first optical fiber is insertable into a subcutaneous tissue layer of the user, and wherein a second end of the optical fiber is positioned proximate the optical sensor; and a second optical conduit comprising a second optical fiber with a first end that is insertable into a subcutaneous tissue layer of the user and a second end that is positioned proximate the optical sensor, the second optical conduit operable to deliver a light input from an optical source to the second end of the optical fiber.